Using a special imaging technique to diagnose breast cancer
Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Breast Cancer
This study is testing a new imaging technique to see if it can help doctors better diagnose breast cancer and make treatment decisions for patients.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | Female |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Dongcheng, Beijing Municipality) |
| Trial ID | NCT06411678 on ClinicalTrials.gov |
What this trial studies
This study involves the use of 68Ga-DOTA-dPNE PET/CT imaging to evaluate the binding of a tracer to breast cancer lesions and assess CD73 expression. The goal is to correlate imaging results with clinical indicators to determine the effectiveness of this imaging technique in diagnosing breast cancer and guiding treatment decisions. By predicting responses to targeted therapies, this study aims to enhance the management of breast cancer patients.
Who should consider this trial
Good fit: Ideal candidates for this study are female patients aged 18 and older with a measurable breast cancer lesion and expected survival of at least 12 weeks.
Not a fit: Patients with severe liver or kidney dysfunction, or those who are pregnant or breastfeeding, may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate diagnoses and better treatment strategies for breast cancer patients.
How similar studies have performed: While this approach is innovative, similar imaging techniques have shown promise in other cancer types, suggesting potential for success in this context.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Female patients aged ≥18 years with an expected survival of at least 12 weeks No prior radiotherapy or chemotherapy; surgery or biopsy is feasible for pathological diagnosis At least one measurable target lesion as defined by RECIST v1.1 Able to provide written informed consent and comply with follow-up requirements Exclusion Criteria: Severe hepatic or renal dysfunction Pregnant, breastfeeding, planning to become pregnant, or planning to have children during the study period; women of childbearing potential must use effective contraception during the study Unable to lie flat for 30 minutes History of claustrophobia or other psychiatric disorders Any other condition deemed unsuitable for participation by the investigator Refusal to participate in the clinical study
Where this trial is running
Dongcheng, Beijing Municipality
- Pumch — Dongcheng, Beijing Municipality, China (Recruiting)
Study contacts
- Principal investigator: Xianzhong ZHANG — Peking Union Medical College Hospital
- Study coordinator: Chenhao JIA
- Email: jiachenhao24@163.com
- Phone: 18548703382
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.